Immutep Limited
IMMP
NASDAQ·Healthcare·Biotechnology·Mkt cap $53.8M
$0.36
▼ -0.05%
P/E
—
Mkt Cap
$53.8M
52-Wk Range
$0.29–$3.53
52-Week Range
$0.29 - $3.53
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 78.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- High volatility (beta 2.2). Larger-than-normal price swings expected.
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Stable
-3.1% over 3m
Quality
Excellent
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying IMMP right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 2, 2026
AUG 30, 2026
Reported EPS of -$0.17 vs -$0.03 consensus (-549.0% surprise). Revenue of $9.9M vs $11.7M expected (-15.2%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-549.0%
Wall Street consensus
2 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: Baird · Mar 13, 2026
vs Industry
How IMMP stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.